PCM
SIOX

Prelude Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Prelude Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16,050
Closed -$883K – 1814
2017
Q3 		$883K Buy
+16,050
New +$2.71M 0.08% 261

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prelude Capital Management's SIOX Position: Q4 2021 in Review

Prelude Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2021, closing a stake of 34,000 shares — an estimated $74K sold.

Prelude Capital Management first reported a position in SIOX in Q4 2016 and held it in 10 quarters. The position peaked at $404K in Q2 2017. 48 funds tracked by Wall St. Rank hold SIOX as of Q4 2021.

  • Prelude Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Prelude Capital Management sold 34,000 Sio Gene Therapies Inc. Common Stock shares in Q4 2021, an estimated $74K.
  • Prelude Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2016 and held it in 10 quarters.
  • Prelude Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $404K in Q2 2017.
  • 48 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2021.

Based on Prelude Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.